SCHEMBL29250568

SCHEMBL29250568

Cn1cc(Nc2ncc(Br)c(Oc3cccc(OC(N)=O)c3)n2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 6/20 0.56
▸ CDK19 Q9BWU1 4/20 0.56
▸ JAK3 P52333 5/20 0.52
▸ SYK P43405 3/20 0.52
▸ GSK3B P49841 3/20 0.52
▸ JAK2 O60674 3/20 0.52
▸ CDC7 O00311 2/20 0.52
▸ DAPK3 O43293 2/20 0.52
▸ ROCK2 O75116 2/20 0.52
▸ PRKD3 O94806 2/20 0.52
▸ MAP4K4 O95819 2/20 0.52
▸ PAK4 O96013 2/20 0.52
▸ PIM1 P11309 2/20 0.52
▸ PRKACA P17612 2/20 0.52
▸ CDK2 P24941 2/20 0.52
▸ CSNK1A1 P48729 2/20 0.52
▸ CLK2 P49760 2/20 0.52
▸ GSK3A P49840 2/20 0.52
▸ CDK7 P50613 2/20 0.52
▸ CDK9 P50750 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584592 1.00 ALK (0.56) ALKCDK19JAK3SYKGSK3B
SCHEMBL29250994 0.85 EGFR (0.46) ALKCDK19JAK3JAK2EGFR
SCHEMBL30584611 0.83 JAK3 (0.47) ALKCDK19JAK3SYKGSK3B
SCHEMBL29250639 0.83 JAK3 (0.47) ALKCDK19JAK3SYKGSK3B
SCHEMBL29250694 0.83 JAK3 (0.42) ALKCDK19JAK3SYKGSK3B
SCHEMBL24392935 0.81 EGFR (0.51) ALKCDK19JAK3SYKGSK3B
SCHEMBL29537972 0.81 EGFR (0.51) ALKCDK19JAK3SYKGSK3B
SCHEMBL29250652 0.81 CDK2 (0.52) ALKCDK19JAK3SYKGSK3B
SCHEMBL30584604 0.80 JAK3 (0.42) ALKCDK19JAK3SYKGSK3B
SCHEMBL29250667 0.80 JAK3 (0.42) ALKCDK19JAK3SYKGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116685583-A Pyrimidine compounds, compositions and pharmaceutical uses thereof 缆图药品公司 2023-09-01 — — CN disclosed
Send feedback